



2020 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan
中華民國血液及骨髓移植學會(TBMT)暨中華民國血液病學會(HST)聯合學術演講年會—日程總表(第一天)

August 1 (Saturday)				
時間/講堂	全球廳(3樓)	環球廳(3樓)		台灣廳(7樓)
08:55	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術演講年會開幕(請會員直接至各會議室聽講)			
09:00-09:45	Satellite Symposium(1) ^{諾華} Moderator: 葉士芃	Satellite Symposium (2) ^{艾伯維} Moderator: 周文堅	09:00-09:45	Satellite Symposium (3) ^{MSD} Moderator: 張正雄
	Eltrombopag in severe aplastic anemia <i>Dr.Cheng-Hong Tsai (Taiwan)</i>	What is standard of care for patients unfit for intensive induction chemotherapy in acute myeloid leukemia <i>Dr. Naval G. Daver (U.S.A.)</i>		The new chapter of cytomegalovirus management for allogeneic hematopoietic stem cell transplant patients <i>Dr.Chieh-Lin Teng (Taiwan)</i>
09:50-10:42	醫師會員演講(1), No.1-4 Hemostasis, Transfusion	醫師會員演講(2), No.5-8 AML-1	10:00-11:30	護理會員演講(I), No.1-6
10:50-11:42	醫師會員演講(3), No.9-12 HSCT	醫師會員演講(4), No.13-16 Lymphoma	11:30-12:15	Break
11:42-12:15	Break, Exhibition, and Poster Viewing			
12:15-13:00	Lunch Symposium(1) ^{諾華} Moderator: 田蕙芬	Lunch Symposium(2) ^{賽基} Moderator: 黃聖懿	12:15-13:00	Lunch Symposium(3) ^{拜耳} Moderator: 陳彩雲
	Evolving treatment landscape of AML with FLT3 mutations <i>Prof.HartmutDöhner (Germany)</i>	NDMM Treatment Goals and Treatment Strategy – Real world experience in Japan <i>Prof. Satoshi Youshihara (Japan)</i>		Copanlisib in the treatment of relapse/ refractory follicular lymphoma: evidence to real world experience <i>Dr.Alexey Danilov(U.S.A.)</i>
13:00-13:05	Break (換場)			
13:05-13:40	TBMT 會員大會 頒發年會贊助商感謝狀	共同會員及 TBMT 會員請至全球廳開會	13:05-13:40	共同會員及 TBMT 會員請至全球廳開會
13:40-14:15	HST 青年研究發展獎口頭研究計畫內容報告及各項學術獎頒獎	共同會員及 HST 會員請至全球廳開會	13:40-15:00	護理專題演講 Moderator: 陳瑞儀
14:15-15:00	HST 會員大會暨理監事選舉			Immune and CAR-T cell therapy in HSCT <i>Dr.Yu-Hsiang Chang (Taiwan)</i>

August 1 (Saturday)				
時間/講堂	全球廳(3樓)	環球廳(3樓)	台灣廳(7樓)	
15:00-15:10	Break, Exhibition, and Poster Viewing			
15:10-15:55	Satellite Symposium(4)^{BMS} Moderator:高志平	Satellite Symposium(5)^{武田} Moderator:滕傑林	15:10-15:55	Satellite Symposium(6)^{艾伯維} Moderator:姚明
	CV/VAE safety in CML patients treated by TKIs <i>Dr.Wei-Ting Chang (Taiwan)</i>	Interpreting clinical trial data in high risk RRMM patient: Translating findings to make difference in the real-world setting <i>Prof.Mario Boccadoro (Italy)</i>		Changing Treatment Paradigm in Chronic Lymphocytic Leukemia <i>Dr. Othman Al-Sawaf (Germany)</i>
16:00-16:45	Keynote Speech (1) - HST Moderator:唐季祿	同步視訊會場	16:00-17:45	護理會員演講(II),No.7-13
	Immunological mess in MDS; is there a target? <i>Dr.Shahram Kordasti(U.K.)</i>			
16:45-17:37	醫師會員演講(5), No.17-20 ALL, CLL	醫師會員演講(6), No. 21-24 New methodology, benign disease		
17:45	第一日會議結束			



2020 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan
中華民國血液及骨髓移植學會(TBMT)暨中華民國血液病學會(HST)聯合學術演講年會一日程總表(第二天)

August 2 (Sunday)			
時間/講堂	全球廳		環球廳
08:00-08:45	Satellite Symposium (7)^{安達} Moderator: 王博南	08:00-08:45	Satellite Symposium (8)^{安斯泰來} Moderator: 譚傳德
	Deepen response and extend survival with carfilzomib in RRMM <i>Dr. Hang Quach (Australia)</i>		Therapeutic paradigm for acute myeloid leukemia with FLT3 mutations <i>Prof. Hitoshi Kiyoi (Japan)</i>
08:45-08:50	Break (換場)		
08:50-09:35	Keynote Speech (2) - TBMT Moderator: 柯博升	同步視訊會場	
	Integrate Fertility Preservation to Clinical Practice <i>Dr. Cheng-Xuan Wu (Taiwan)</i>		
09:35-09:40	Break (換場)		
09:40-10:45	醫師會員演講(7), No. 25-29 AML-2	09:40-10:45	醫師會員演講(8), No. 30-34 Pediatric Hematology
10:50-12:08	醫師會員演講(9), No.35-40 MDS, MPN	10:45-12:29	HST 臨床試驗工作組報告 I-VIII
12:30	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術演講年會閉幕		

- 備註：
- ※發表者請事先準備 Power Point 簡報檔案，於發表前一個小時至試片處測試並繳交簡報檔案，以利會議順利進行。
 - ※外賓演講及 Satellite Symposiums：每題 45 分鐘，其中包括 35 分鐘「演講」、10 分鐘「討論」。30 分鐘鈴響一聲，35 分鐘鈴響兩聲，請結束演講。
 - ※醫師會員演講及 HST 臨床試驗工作組報告：每題 13 分鐘，其中包括 10 分鐘「演講」、3 分鐘「討論」。9 分鐘鈴響一聲，10 分鐘鈴響兩聲，請結束演講。
 - ※護理會員演講：每題 15 分鐘，其中包括 10 分鐘「演講」、5 分鐘「討論」，9 分鐘鈴響一聲，10 分鐘鈴響兩聲，請結束演講。
 - ※壁報論文展示區：3 樓環球廳對面開放空間。
 - ※繼續教育學分：中華民國血液病學會甲類 15 分、中華民國血液及骨髓移植學會 15 分。
 - ※午餐便當：全體會員可至全球廳、環球廳或 7 樓台灣廳門口領取餐點並聆聽演講。



TBMT-HST 聯合學術年會演講題目、編號及時間細表(醫師部分)

August 1 (Saturday)		
時間/講堂	全球廳	環球廳
08:55	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術年會開幕 (請會員直接至各會議室聽講)	
09:50-10:42	醫師會員演講(1) No.01-04 Hemostasis, Transfusion Moderator: 余垣斌、林敬業	醫師會員演講(2) No.05-08 AML-1 Moderator: 侯信安、劉益昌
09:50-10:03	⁰¹ The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 von Willebrand disease 陳宇欽/台北，三軍總醫院	⁰⁵ Investigating the roles of DOCK1 gene in hematopoiesis and its clinical and biological significance in acute myeloid leukemia 林明恩/2019 年度麒麟青年研究發展獎 成果報告
10:03-10:16	⁰² High bleeding rates and associated risk factors in patients with chronic hepatitis B and C 黃慈恩/嘉義，嘉義長庚醫院	⁰⁶ Frontline treatment with venetoclax, posaconazole, and standard dose cytarabine or azacitidine followed by allogeneic hematopoietic stem cell transplantation for newly diagnosed acute myeloid leukemia 譚傳德/台北，和信治癌中心醫院
10:16-10:29	⁰³ Regular Prophylaxis with rFVIII-Fc for Patients with Severe Hemophilia A: Prophylaxis Rates, Regimen, Clinical Correlates, and the Benefits for Joint Health 張家堯/台北，台北醫學大學附設醫院	⁰⁷ Measurable/Minimal Residual Disease (MRD) Monitoring by Next-Generation Sequencing in Patients with Acute Myeloid Leukemia Can Predict Clinical Outcomes 蔡承宏/台北，台大醫院
10:29-10:42	⁰⁴ Infection as the major cause of mortality of acquired hemophilia: experience from a relatively elderly cohort 張鴻/桃園，林口長庚醫院	⁰⁸ The Clinical Association and Prognostic Impact of IL1RAP in de novo Acute Myeloid Leukemia 李婉瑄/台北，台大醫院
10:50-11:42	醫師會員演講(3) No.09-12 HSCT Moderator: 盧孟佑、陳宇欽	醫師會員演講(4) No.13-16 Lymphoma Moderator: 劉峻宇、張鴻
10:50-11:03	⁰⁹ Total Marrow and Lymphoid Irradiation(TMLI) conditioning for Allogeneic Hematopoietic Stem Cell Transplantation(HSCT): China Medical University Hospital(CMUH) experience. 王秀慈/台中，中國醫藥大學附設醫院	¹³ BET inhibition subdues Rho/RAS-mediated migration and upregulates IQGAP3, a novel prognostic indicator in PI3K-activated diffuse large B-cell lymphoma 陳志丞/嘉義，嘉義長庚醫院
11:03-11:16	¹⁰ CMV prophylaxis in Allogeneic hematopoietic stem cell transplantation 李柏憲/台中，台中榮民總醫院	¹⁴ The Effect of Hepatitis B Virus Infection on Clinical Features and Prognosis in Patients with Follicular Lymphoma in The Rituximab Era 鄭傑隆/台北，台大醫院



August 1 (Saturday)		
時間/講堂	全球廳	環球廳
11:16-11:29	11 The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Myeloma Patients Receiving Autologous Hematopoietic Stem Cell Transplantation 劉嘉仁/台北，台北榮民總醫院	15 Outcomes for Double Hit Lymphoma Patients in Taichung Veterans General Hospital 李宥丞/台中，台中榮民總醫院
11:29-11:42	12 Donor CD4- invariant NK T lymphocytes attenuate acute graft versus host disease in mice 李思慧/台北，台成細胞治療中心	16 Intensive Chemo-immunotherapy plus Hematopoietic Stem Cell Transplantation or Non-intensive Treatment for Mantle Cell Lymphoma -- Real World Clinical Outcome in Single Institute Experience 譚傳德/台北，和信治癌中心醫院
16:45-17:37	醫師會員演講(5) No.17-20 ALL, CLL Moderator: 邱世欣、何景良	醫師會員演講(6) No.21-24 New methodology, benign disease Moderator: 吳懿峰、陳淑惠
16:45-16:58	17 The Immunophenotypic Pattern of BCR-ABL Mutation in Acute Lymphoblastic Leukemia 柯亞倫/高雄，高雄醫學大學附設醫院	21 FLOW-FISH 2.0 — Methodology Development and Clinical Exploration 吳尚儒/2019 年度 Sysmex 精準醫學研究發展獎成果報告
16:58-17:11	18 Post-HSCT relapsed precursor B-ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: two case reports 黃威翰/花蓮，花蓮慈濟醫院	22 Automatic bone marrow cell identification and classification by deep neural network 尤達權/台北，雲林台大醫院
17:11-17:24	19 Outcome in adolescent and young adult (AYA) patients treated for high risk B-precursor acute lymphoblastic leukemia 蘇羿困/桃園，林口長庚醫院	23 Iron status and the prevalence of anemia among Taiwanese women with common variants of the Tmprss6 rs855791: a cross-sectional study. 裴松南/高雄，義大癌治療醫院
17:24-17:37	20 Role of inhibition of phosphoinositide-3-kinase-akt-mTOR and cell cycle check point pathway in the treatment of lymphocytic leukemia, an in vitro and in vivo study 蘇裕傑/高雄，義大醫院	24 Variation in Tmprss6 (SNP rs855791) effects iron metabolism and oral iron absorption – a stable iron isotope study in Taiwanese women 裴松南/高雄，義大癌治療醫院



TBMT-HST 聯合學術年會演講題目、編號及時間細表(醫師部分)

August 2 (Sunday)		
時間/講堂	全球廳	環球廳
09:40-10:45	<p>醫師會員演講(7) No.25-29 AML-2 Moderator:邱宗傑、林世強</p>	<p>醫師會員演講(8) No.30-34 Pediatric Hematology Moderator:周獻堂、巫康熙</p>
09:40-09:53	<p>²⁵ Epidemiology of invasive fungal infection in acute myeloid leukemia patients receiving primary antifungal prophylaxis during induction chemotherapy <i>王幸婷/台中，中國醫藥大學附設醫院</i></p>	<p>³⁰ Long-term outcomes of juvenile myelomonocytic leukemia in Taiwan – TPOG experience <i>周書緯/台北，台大醫院</i></p>
09:53-10:06	<p>²⁶ Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling <i>羅旻諤/台北，台大醫院</i></p>	<p>³¹ Childhood Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis in Taiwan <i>王德勳/台北，三軍總醫院</i></p>
10:06-10:19	<p>²⁷ A phase I study of ADI-PEG20 plus low dose cytarabine for relapsed/refractory or poor-risk acute myeloid leukemia patients <i>顏志傑/台南，成大醫院</i></p>	<p>³² High Frequency of Heat Shock Protein 27 (Hsp27) Over-Expression is Useful for Minimal Residual Disease Detection in Children with B-Cell Acute Lymphoblastic Leukemia <i>周書緯/台北，台大醫院</i></p>
10:19-10:32	<p>²⁸ Minimal residual disease detection by real-time quantitative PCR for IDH2 mutations in AML patients: the stability and correlation with other genetic markers <i>高小雯/桃園，林口長庚醫院</i></p>	<p>³³ The treatment outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in children <i>陳世翔/桃園，林口長庚醫院</i></p>
10:32-10:45	<p>²⁹ Impact of cytoreduction strategy and mutations on post-transplantation outcome in acute myeloid leukemia with myelodysplastic-related change <i>田豐銘/台北，台大癌醫中心醫院</i></p>	<p>³⁴ Impact of Minimal Residual Disease Monitoring on Outcomes of Childhood Core Binding Factor Acute Myeloid Leukemia <i>葉庭吉/台北，馬偕兒童醫院</i></p>
10:50-12:08	<p>醫師會員演講(9) No.35-40 MDS, MPN Moderator:陳志丞、王全正</p>	<p>HST 臨床試驗工作組報告 I-VIII</p>
10:50-11:03	<p>³⁵ An Immune Signature-Based Scoring System Could Independently Predict the Prognosis of Myelodysplastic Syndrome Patients <i>王昱弘/台北，台大醫院</i></p>	
11:03-11:16	<p>³⁶ Clinical Manifestations of Patients with Myelodysplastic Syndromes and the</p>	

August 2 (Sunday)		
時間/講堂	全球廳	環球廳
	Impact of Azacitidine Treatment on High-risk Patients <i>歐哲璋/桃園，林口長庚</i>	
11:16-11:29	³⁷ Taiwan MPN Landmark Survey: Impact of Myeloproliferative Neoplasms (MPNs) and Perceptions of Treatment Goals Amongst Physicians and Patients <i>張正雄/彰化，彰濱秀傳紀念醫院</i>	
11:29-11:42	³⁸ IDH mutation accelerates myelofibrosis in an in vivo TPO mouse model <i>林建崧/台北，台大醫院</i>	
11:42-11:55	³⁹ Combination treatment of midostaurin and azacitidine in a patient with systemic mastocytosis associated with chronic myelomonocytic leukemia: Clinical and single-cell DNA sequencing analysis <i>林建鴻/台北，馬偕紀念醫院</i>	
11:55-12:08	⁴⁰ High expression of PD-L1 in megakaryocytes is associated with JAK2 and high molecular risk mutations in primary myelofibrosis patients. <i>魏兆宏/台北，台大醫院</i>	

備註：

☺ 榮獲 HST 青年優秀論文報告獎肯定或青年研究發展獎肯定。

※ 發表者請事先準備 Power Point 簡報檔案，於發表前一個小時至試片處測試並繳交簡報檔案，以利會議順利進行。

※ 外賓演講及 Satellite Symposiums：每題 45 分鐘，其中包括 35 分鐘「演講」、10 分鐘「討論」。

30 分鐘鈴響一聲，35 分鐘鈴響兩聲，請結束演講。

※ 醫師會員演講及 HST 臨床試驗工作組報告：每題 13 分鐘，其中包括 10 分鐘「演講」、3 分鐘「討論」。9 分鐘鈴響一聲，10 分鐘鈴響兩聲，請結束演講。

※ 護理會員演講：每題 15 分鐘，其中包括 10 分鐘「演講」、5 分鐘「討論」，9 分鐘鈴響一聲，10 分鐘鈴響兩聲，請結束演講。

※ 壁報論文展示區：3 樓環球廳對面開放空間。

※ 繼續教育學分：中華民國血液病學會甲類 15 分、中華民國血液及骨髓移植學會 15 分、

※ 午餐：全體會員可至全球廳、環球廳或 7 樓台灣廳門口領取餐點並聆聽演講。